Clinical trial
Efficacy and Safety of Short-course Radiotherapy Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of Microsatellite Stable Locally Advanced Rectal Cancer: a Single-centre, Single-arm, Phase 2 Study
NCT05576480 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Short-course Radiotherapy Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of Microsatellite Stable Locally Advanced Rectal Cancer: a Single-centre, Single-arm, Phase 2 Study
- Lead sponsor
- Ruijin Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 6, 2023
- Completion date
- December 31, 2026
- Enrollment
- 55 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced, rectal cancer